TABLE 2

EC₅₀ values determined in 2D assays with leukemic cells derived from bone marrow cells of first-line AML patients (n = 14) treated in vitro with various concentrations of volasertib (0.5 nM to 10 μM)

EC₅₀ values were measured after 96 hours. Results from a single experiment with 14 different samples, each measured in triplicate, are shown.

Sample	Previous MDS/MPS	Karyotype ISCN 2005	FAB	Cytogenetic Risk Group Classification	FLT3-ITD	NPM1	Other Mutations or Rearrangements	EC₅₀
								nM
Cohort 1 Sample 6	No	48,XY,+8,+21[6]/46,XY[9]	M5a	Intermediate	No	pos	WT1+	24
Cohort 2 Sample 1	No	46,XX	M5	Intermediate	nd	nd		18
Cohort 2 Sample 2	No	45,XY,-7 [7]/45,XY, der(3)del (3) (p11p21),-7 [22]	M2	High	No	neg		59
Cohort 2 Sample 3	No	46,XY [20]	AML with myelodysplasia-related changes	Intermediate	No	neg	WT1+	43
Cohort 2 Sample 4	No	46,XX,add(9)(q34),t(11;19)(q23;p13.3[18]/ 46,XX[2]	M5	High	No	neg	MLL-ENL+	14
Cohort 2 Sample 5	No	46,XY,t(9;11)(p11;q23)[20]	M5a	High	nd	nd		27
Cohort 2 Sample 6	No	46,XY [20]	M4	Intermediate	No	neg	WT1+	99
Cohort 2 Sample 7	No	46,XX	M2	Intermediate	No	neg	WT1+	21
Cohort 2 Sample 9	No	Unknown	Unknown	Unknown	Yes	pos	WT1+	8
Cohort 2 Sample 10	Yes	46,XY, inv(9)(p11q13) c[20]	M5a	Intermediate	No	neg		39
Cohort 2 Sample 12	No	46,XX,t(9;11)(p22;q23)[20]	M4	High	No	neg	WT1+, EVI1+	34
Cohort 2 Sample 14	No	46,XX	M4	Intermediate	No	pos	WT1+	53
Cohort 2 Sample 15	No	46,XY [20]	M1	Intermediate	Yes	pos		377
Cohort 2 Sample 16	Yes	46,XY [20]	M4	Intermediate	No	neg	DNMT3A exon 7+	22

FAB, French-American-British; ISCN, International System of Cytogenetic Nomenclature; ITD, internal tandem duplication; MDS, Myelodysplastic syndrome; MPS, Myeloproliferative syndrome; nd, not determined; neg, negative; pos, positive.